Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Published:2020-09 Issue:9 Volume:21 Page:e412
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yang† Xu,Wang† Dongxu,Lin Jianzhen,Yang Xiaobo,Zhao Haitao

Publisher

Elsevier BV

Subject

Oncology

Reference5 articles.

1. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study;Lee;Lancet Oncol,2020

2. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

3. Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma;Lu;Liver Cancer,2019

4. Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC);Kim;Proc Am Soc Clin Oncol,2020

5. LBA38_PR - CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC);Yau;Ann Oncol,2019

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy;Scientific Reports;2024-08-09

2. Long-Term Follow-Up of Combination Therapy with Sintilimab and Anlotinib in Gallbladder Follicular Dendritic Cell Sarcoma: A Rare Case Report;OncoTargets and Therapy;2024-04

3. Role of Cancer Stem Cells in Drug Resistance;Drug Resistance in Cancer: Mechanisms and Strategies;2024

4. Inhibiting Endothelial Cell‐Mediated T Lymphocyte Apoptosis with Integrin‐Targeting Peptide‐Drug Conjugate Filaments for Chemoimmunotherapy of Triple‐Negative Breast Cancer;Advanced Materials;2023-11-30

5. Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case;Journal of Cancer Research and Clinical Oncology;2023-02-08